These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

794 related items for PubMed ID: 20981785

  • 1. Low rate of virological failure and maintenance of susceptibility to HIV-1 protease inhibitors with first-line lopinavir/ritonavir-based antiretroviral treatment in clinical practice.
    Prosperi MC, Zazzi M, Punzi G, Monno L, Colao G, Corsi P, Di Giambenedetto S, Meini G, Ghisetti V, Bonora S, Pecorari M, Gismondo MR, Bagnarelli P, Carli T, De Luca A, ARCA Collaborative Group.
    J Med Virol; 2010 Dec; 82(12):1996-2003. PubMed ID: 20981785
    [Abstract] [Full Text] [Related]

  • 2. Effects of nucleoside reverse transcriptase inhibitor backbone on the efficacy of first-line boosted highly active antiretroviral therapy based on protease inhibitors: meta-regression analysis of 12 clinical trials in 5168 patients.
    Hill A, Sawyer W.
    HIV Med; 2009 Oct; 10(9):527-35. PubMed ID: 19785663
    [Abstract] [Full Text] [Related]

  • 3. Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.
    Prescrire Int; 2004 Aug; 13(72):144-50. PubMed ID: 15532140
    [Abstract] [Full Text] [Related]

  • 4. Long-term (96-week) follow-up of antiretroviral-naïve HIV-infected patients treated with first-line lopinavir/ritonavir monotherapy in the MONARK trial.
    Ghosn J, Flandre P, Cohen-Codar I, Girard PM, Chaix ML, Raffi F, Dellamonica P, Ngovan P, Norton M, Delfraissy JF, MONARK Study Group.
    HIV Med; 2010 Feb; 11(2):137-42. PubMed ID: 19682100
    [Abstract] [Full Text] [Related]

  • 5. Ability of different lopinavir genotypic inhibitory quotients to predict 48-week virological response in highly treatment-experienced HIV-infected patients receiving lopinavir/ritonavir.
    Gianotti N, Galli L, Danise A, Hasson H, Boeri E, Lazzarin A, Castagna A.
    J Med Virol; 2006 Dec; 78(12):1537-41. PubMed ID: 17063520
    [Abstract] [Full Text] [Related]

  • 6. Time to virological failure with atazanavir/ritonavir and lopinavir/ritonavir, with or without an H2-receptor blocker, not significantly different in HIV observational database study.
    Keiser PH, Nassar N.
    Int J STD AIDS; 2008 Aug; 19(8):561-2. PubMed ID: 18663047
    [Abstract] [Full Text] [Related]

  • 7. The use of drug resistance algorithms and genotypic inhibitory quotient in prediction of lopinavir-ritonavir treatment response in human immunodeficiency virus type 1 protease inhibitor-experienced patients.
    Maillard A, Chapplain JM, Tribut O, Bentué-Ferrer D, Tattevin P, Arvieux C, Michelet C, Ruffault A.
    J Clin Virol; 2007 Feb; 38(2):131-8. PubMed ID: 17208042
    [Abstract] [Full Text] [Related]

  • 8. Determinants of virological failure after successful viral load suppression in first-line highly active antiretroviral therapy.
    Geretti AM, Smith C, Haberl A, Garcia-Diaz A, Nebbia G, Johnson M, Phillips A, Staszewski S.
    Antivir Ther; 2008 Feb; 13(7):927-36. PubMed ID: 19043927
    [Abstract] [Full Text] [Related]

  • 9. Lopinavir/ritonavir monotherapy or plus zidovudine and lamivudine in antiretroviral-naive HIV-infected patients.
    Delfraissy JF, Flandre P, Delaugerre C, Ghosn J, Horban A, Girard PM, Norton M, Rouzioux C, Taburet AM, Cohen-Codar I, Van PN, Chauvin JP.
    AIDS; 2008 Jan 30; 22(3):385-93. PubMed ID: 18195565
    [Abstract] [Full Text] [Related]

  • 10. The NIQ of lopinavir is predictive of a 48-week virological response in highly treatment-experienced HIV-1-infected subjects treated with a lopinavir/ritonavir-containing regimen.
    Castagna A, Gianotti N, Galli L, Danise A, Hasson H, Boeri E, Hoetelmans R, Nauwelaers D, Lazzarin A.
    Antivir Ther; 2004 Aug 30; 9(4):537-43. PubMed ID: 15456085
    [Abstract] [Full Text] [Related]

  • 11. Efficacy and safety of ritonavir-boosted dual protease inhibitor therapy in antiretroviral-naive HIV-1-infected patients: the 2IP ANRS 127 study.
    Landman R, Capitant C, Descamps D, Chazallon C, Peytavin G, Katlama C, Pialoux G, Bentata M, Brun-Vézinet F, Aboulker JP, Yéni P, ANRS 127 Study Group.
    J Antimicrob Chemother; 2009 Jul 30; 64(1):118-25. PubMed ID: 19420019
    [Abstract] [Full Text] [Related]

  • 12. Safety and antiviral activity at 48 weeks of lopinavir/ritonavir plus nevirapine and 2 nucleoside reverse-transcriptase inhibitors in human immunodeficiency virus type 1-infected protease inhibitor-experienced patients.
    Benson CA, Deeks SG, Brun SC, Gulick RM, Eron JJ, Kessler HA, Murphy RL, Hicks C, King M, Wheeler D, Feinberg J, Stryker R, Sax PE, Riddler S, Thompson M, Real K, Hsu A, Kempf D, Japour AJ, Sun E.
    J Infect Dis; 2002 Mar 01; 185(5):599-607. PubMed ID: 11865416
    [Abstract] [Full Text] [Related]

  • 13. Treatment outcomes amongst previously antiretroviral-naïve HIV-infected patients starting lopinavir/ritonavir-containing antiretroviral regimens at the Royal Free Hospital.
    Smith CJ, Phillips AN, Youle MS, Sabin CA, Lampe FC, Tsintas R, Tyrer M, Johnson MA.
    HIV Med; 2007 Jan 01; 8(1):55-63. PubMed ID: 17305933
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection.
    Walmsley S, Bernstein B, King M, Arribas J, Beall G, Ruane P, Johnson M, Johnson D, Lalonde R, Japour A, Brun S, Sun E, M98-863 Study Team.
    N Engl J Med; 2002 Jun 27; 346(26):2039-46. PubMed ID: 12087139
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Lopinavir/ritonavir or efavirenz plus two nucleoside analogues as first-line antiretroviral therapy: a non-randomized comparison.
    De Luca A, Cozzi-Lepri A, Antinori A, Zaccarelli M, Bongiovanni M, Di Giambenedetto S, Marconi P, Cicconi P, Resta F, Grisorio B, Ciardi M, Cauda R, Monforte Ad, I.Co.N.A, UCSC, IMIT-MI, INMI.
    Antivir Ther; 2006 Jun 27; 11(5):609-18. PubMed ID: 16964829
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Predictive value of HIV-1 protease genotype and virtual phenotype on the virological response to lopinavir/ritonavir-containing salvage regimens.
    Loutfy MR, Raboud JM, Walmsley SL, Saskin R, Montaner JS, Hogg RS, Thompson CA, Harrigan PR.
    Antivir Ther; 2004 Aug 27; 9(4):595-602. PubMed ID: 15456091
    [Abstract] [Full Text] [Related]

  • 20. Selection of resistance in protease inhibitor-experienced, human immunodeficiency virus type 1-infected subjects failing lopinavir- and ritonavir-based therapy: mutation patterns and baseline correlates.
    Mo H, King MS, King K, Molla A, Brun S, Kempf DJ.
    J Virol; 2005 Mar 27; 79(6):3329-38. PubMed ID: 15731227
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 40.